表纸
市场调查报告书

前列腺肥大症治疗的全球市场:产业分析,规模,占有率,成长,趋势,及预测

Benign Prostatic Hyperplasia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

出版商 Transparency Market Research 商品编码 910592
出版日期 内容资讯 英文 220 Pages
商品交期: 最快1-2个工作天内
价格
前列腺肥大症治疗的全球市场:产业分析,规模,占有率,成长,趋势,及预测 Benign Prostatic Hyperplasia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
出版日期: 2019年08月21日内容资讯: 英文 220 Pages
简介

本报告提供全球前列腺肥大症治疗的相关调查,提供市场机会和趋势,成长及阻碍因素,治疗·终端用户·各地区的市场分析,竞争情形,主要企业的简介等资讯。

目录

第1章 序文

  • 报告的范围及市场区隔
  • 调查亮点

第2章 假设及调查方法

  • 所使用的假设及简称
  • 调查方法

第3章 摘要整理

  • 市场规模及分布:各地区
  • 市场概述

第4章 市场概要

  • 治疗概要
  • 主要产业的发展
  • 市场动态
  • 成长及阻碍因素的概述分析
  • 成长要素
  • 阻碍因素
  • 市场机会
  • 市场收益预测

第5章 重要的洞察

  • 临床试验的开发平台分析
  • 美国的盛行率
  • 偿付方案
  • 主要的合并及收购
  • 手术数
  • 各企业的竞争市场占有率分析
  • 治疗的平均成本
  • 产品/品牌分析
    • Urolift
    • Rezum

第6章 市场分析:不同治疗

  • 简介
  • 市场规模及预测
    • 药物类别
    • 微创手术
    • 雷射治疗
    • 其他
  • 市场分析
  • 市场魅力分析

第7章 市场分析:各终端用户

  • 简介
  • 市场规模及预测
    • 医院
    • 门诊病人手术中心
    • 专门诊所
    • 其他
  • 市场分析
  • 市场魅力分析

第8章 市场分析:各地区

  • 市场规模及预测
    • 北美
    • 欧洲
    • 亚太地区
    • 南美
    • 中东·非洲
  • 市场分析
  • 市场魅力分析

第9章 北美

第10章 欧洲

第11章 亚太地区

第12章 南美

第13章 中东及非洲

第14章 竞争情形(制药公司)

  • 企业简介
    • Abbott
    • Allergan plc
    • Astellas Pharma, Inc.
    • 旭化成株式会社
    • Boehringer Ingelheim GmbH
    • GlaxoSmithKline plc
    • Pfizer, Inc.
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.

第15章 竞争情形(医疗设备/服务供应商)

  • 企业简介
    • Boston Scientific Corporation
    • Teleflex Incorporated
    • Endo International plc
    • Urologix, LLC
    • LISA Laser
    • Olympus Corporation
目录

Title:
Benign Prostatic Hyperplasia Treatment Market (Treatment: Drug Class, Minimally Invasive Surgeries, Laser Therapy, and Others; End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027.

Scope of the Report

Transparency Market Research (TMR), in its recently published research report, quantifies the growth of the benign prostatic hyperplasia treatment market during the forecast period of 2019-2027. This exclusive research report on the global benign prostatic hyperplasia treatment market offers a detailed overview of the benign prostatic hyperplasia treatment market, uncovering significant aspects and segmentations based on numerous parameters. This comprehensive research report also talks about the research methodologies being adopted in order to estimate precise market numbers. This detailed business guide also includes relevant charts and tables, in order to enable stakeholders get an incisive outlook of the benign prostatic hyperplasia treatment market for the forecast period.

This statistical business report analyzes, at length, crucial insights obtained by this exclusive study. With the aid of rare and distinguished insights enumerated in this comprehensive research report, stakeholders in the benign prostatic hyperplasia treatment market can form business growth strategies to gain an upper hand over their competitors. Various factors accounted for the benign prostatic hyperplasia treatment market's upward growth trajectory are discussed at length in this research report. Additionally, the research report identifies and explains the key drivers, threats, restraints, and opportunities present in the benign prostatic hyperplasia treatment market.

This broad study of the global benign prostatic hyperplasia treatment market assesses the growth drivers and restraints at length. This exhaustive study of important factors can aid market players in understanding the challenges present in the benign prostatic hyperplasia treatment market during the forecast period of 2019-2027. The detailed research report gauges the bargaining power of buyers and suppliers, threats arising from new market entrants and substitutes, and the degree of competition present in the benign prostatic hyperplasia treatment market. Influence exerted on the benign prostatic hyperplasia treatment market by the government policies is also discussed in this research report.

Segmentation

This comprehensive research report encompasses the technological advancements and recent trends to gain a better perspective of the growth of the benign prostatic hyperplasia treatment market. In order to aid market players in having a precise market approach, our analysts have bifurcated the benign prostatic hyperplasia treatment market into key segments - treatment, end user, and region. Key segments of the benign prostatic hyperplasia treatment market are as mentioned below:

Key Questions Answered:

This comprehensive research report analyzes and answers crucial questions related to the growth of the benign prostatic hyperplasia treatment market during the forecast period.

Some of the key questions answered in this study are as follows:

  • What are the key developments and important market shifts expected to be observed in the benign prostatic hyperplasia treatment market during the forecast period of 2019-2027?
  • What are the key strategies followed by market participants functioning in the benign prostatic hyperplasia treatment market?
  • What are some of the important recent developments that the new market participants should look at?
  • Which treatment will be the top-selling one in the benign prostatic hyperplasia treatment market?

Research Methodology

The research approach taken by analysts at Transparency Market Research (TMR) includes a robust methodology for obtaining key insights into the benign prostatic hyperplasia treatment market for the forecast period of 2019-2027. Interviews were conducted with important market participants, opinion leaders, vendors, distributors, and industry experts. In addition to this, a detailed secondary study of company websites, industry associations, marketing collaterals, and government statistics is carried out.

Table of Contents

1. Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Assumptions and Acronyms Used
  • 2.2. Research Methodology

3. Executive Summary

  • 3.1. Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027
  • 3.2. Global Benign Prostatic Hyperplasia Treatment Market: Market Snapshot

4. Market Overview

  • 4.1. Global Benign Prostatic Hyperplasia Treatment Market: Treatment Overview
  • 4.2. Global Benign Prostatic Hyperplasia Treatment Market: Key Industry Developments
  • 4.3. Market Dynamics
  • 4.4. Drivers and Restraints Snapshot Analysis
  • 4.5. Drivers
    • 4.5.1. Increasing Aging Men Population All Over the World
    • 4.5.2. Expanding Patient Pool Due to Other Risk Factors
  • 4.6. Restraints
    • 4.6.1. Insufficient Healthcare Facilities and Unawareness of BPH Condition
    • 4.6.2. Patent Expiration of Benign Prostatic Hyperplasia Drugs
  • 4.7. Opportunities
  • 4.8. Global Benign Prostatic Hyperplasia Treatment Market Revenue Projections (US$ Mn), 2017-2027

5. Key Insights

  • 5.1. Clinical Trial Pipeline Analysis
  • 5.2. U.S. Prevalence of Benign Prostatic Hyperplasia
  • 5.3. Re-imbursement Scenario
  • 5.4. Key Merger and Acquisitions
  • 5.5. Number of Surgeries (Unit Procedures) Performed, 2018
  • 5.6. Competitive Market Share Analysis, by Company, 2018
  • 5.7. Average Cost of Benign Prostatic Hyperplasia Treatment
  • 5.8. Product/Brand Analysis - 2018
    • 5.8.1. Urolift
    • 5.8.2. Rezum

6. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Treatment

  • 6.1. Introduction
  • 6.2. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
    • 6.2.1. Drug Class
      • 6.2.1.1. Alpha-blockers
      • 6.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
      • 6.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
      • 6.2.1.4. Others
    • 6.2.2. Minimally Invasive Surgeries
      • 6.2.2.1. Transurethral Resection of the Prostate (TURP)
      • 6.2.2.2. Transurethral Incision of the Prostate (TUIP)
      • 6.2.2.3. Robotic Surgeries
      • 6.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
      • 6.2.2.5. Prostatic Urethral Lift
      • 6.2.2.6. Others
    • 6.2.3. Laser Therapy
    • 6.2.4. Others
  • 6.3. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Treatment
  • 6.4. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment

7. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by End-user

  • 7.1. Introduction
  • 7.2. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
    • 7.2.1. Hospitals
    • 7.2.2. Ambulatory Surgical Centers
    • 7.2.3. Specialty Clinics
    • 7.2.4. Others
  • 7.3. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by End-user
  • 7.4. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user

8. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Region

  • 8.1. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Region, 2017-2027
    • 8.1.1. North America
    • 8.1.2. Europe
    • 8.1.3. Asia Pacific
    • 8.1.4. Latin America
    • 8.1.5. Middle East & Africa
  • 8.2. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Region
  • 8.3. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Region

9. North America Benign Prostatic Hyperplasia Treatment Market Analysis

  • 9.1. North America Benign Prostatic Hyperplasia Treatment Market
  • 9.2. North America Benign Prostatic Hyperplasia Treatment Market Overview
  • 9.3. North America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
    • 9.3.1. Drug Class
      • 9.3.1.1. Alpha-blockers
      • 9.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
      • 9.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
      • 9.3.1.4. Others
    • 9.3.2. Minimally Invasive Surgeries
      • 9.3.2.1. Transurethral Resection of the Prostate (TURP)
      • 9.3.2.2. Transurethral Incision of the Prostate (TUIP)
      • 9.3.2.3. Robotic Surgeries
      • 9.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
      • 9.3.2.5. Prostatic Urethral Lift
      • 9.3.2.6. Others
    • 9.3.3. Laser Therapy
    • 9.3.4. Others
  • 9.3.5.
  • 9.4. North America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
    • 9.4.1. Hospitals
    • 9.4.2. Ambulatory Surgical Centers
    • 9.4.3. Specialty Clinics
    • 9.4.4. Others
  • 9.5. North America Benign Prostatic Hyperplasia Treatment Market Forecast, by Country
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. North America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
    • 9.6.1. By Treatment
    • 9.6.2. By End-user
    • 9.6.3. By Country

10. Europe Benign Prostatic Hyperplasia Treatment Market Analysis

  • 10.1. Europe Benign Prostatic Hyperplasia Treatment Market
  • 10.2. Europe Benign Prostatic Hyperplasia Treatment Market Overview
  • 10.3. Europe Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
    • 10.3.1. Drug Class
      • 10.3.1.1. Alpha-blockers
      • 10.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
      • 10.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
      • 10.3.1.4. Others
    • 10.3.2. Minimally Invasive Surgeries
      • 10.3.2.1. Transurethral Resection of the Prostate (TURP)
      • 10.3.2.2. Transurethral Incision of the Prostate (TUIP)
      • 10.3.2.3. Robotic Surgeries
      • 10.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
      • 10.3.2.5. Prostatic Urethral Lift
      • 10.3.2.6. Others
    • 10.3.3. Laser Therapy
    • 10.3.4. Others
  • 10.4. Europe Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
    • 10.4.1. Hospitals
    • 10.4.2. Ambulatory Surgical Centers
    • 10.4.3. Specialty Clinics
    • 10.4.4. Others
  • 10.5. Europe Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
    • 10.5.1. U.K.
    • 10.5.2. France
    • 10.5.3. Germany
    • 10.5.4. Spain
    • 10.5.5. Italy
    • 10.5.6. Rest of Europe
  • 10.6. Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
    • 10.6.1. By Treatment
    • 10.6.2. By End-user
    • 10.6.3. By Country/Sub-region

11. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis

  • 11.1. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Key Findings
  • 11.2. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Overview
  • 11.3. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
    • 11.3.1. Drug Class
      • 11.3.1.1. Alpha-blockers
      • 11.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
      • 11.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
      • 11.3.1.4. Others
    • 11.3.2. Minimally Invasive Surgeries
      • 11.3.2.1. Transurethral Resection of the Prostate (TURP)
      • 11.3.2.2. Transurethral Incision of the Prostate (TUIP)
      • 11.3.2.3. Robotic Surgeries
      • 11.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
      • 11.3.2.5. Prostatic Urethral Lift
      • 11.3.2.6. Others
    • 11.3.3. Laser Therapy
    • 11.3.4. Others
  • 11.4. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
    • 11.4.1. Hospitals
    • 11.4.2. Ambulatory Surgical Centers
    • 11.4.3. Specialty Clinics
    • 11.4.4. Others
  • 11.5. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
    • 11.5.1. China
    • 11.5.2. India
    • 11.5.3. Japan
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
    • 11.6.1. By Treatment
    • 11.6.2. By End-user
    • 11.6.3. By Country/Sub-region

12. Latin America Benign Prostatic Hyperplasia Treatment Market Analysis

  • 12.1. Latin America Benign Prostatic Hyperplasia Treatment Market Key Findings
  • 12.2. Latin America Benign Prostatic Hyperplasia Treatment Market Overview
  • 12.3. Latin America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
    • 12.3.1. Drug Class
      • 12.3.1.1. Alpha-blockers
      • 12.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
      • 12.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
      • 12.3.1.4. Others
    • 12.3.2. Minimally Invasive Surgeries
      • 12.3.2.1. Transurethral Resection of the Prostate (TURP)
      • 12.3.2.2. Transurethral Incision of the Prostate (TUIP)
      • 12.3.2.3. Robotic Surgeries
      • 12.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
      • 12.3.2.5. Prostatic Urethral Lift
      • 12.3.2.6. Others
    • 12.3.3. Laser Therapy
    • 12.3.4. Others
  • 12.4. Latin America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
    • 12.4.1. Hospitals
    • 12.4.2. Ambulatory Surgical Centers
    • 12.4.3. Specialty Clinics
    • 12.4.4. Others
  • 12.5. Latin America Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
    • 12.6.1. By Treatment
    • 12.6.2. By End-user
    • 12.6.3. By Country/Sub-region

13. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Analysis

  • 13.1. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market
  • 13.2. Benign Prostatic Hyperplasia Treatment Market Overview
  • 13.3. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
    • 13.3.1. Drug Class
      • 13.3.1.1. Alpha-blockers
      • 13.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
      • 13.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
      • 13.3.1.4. Others
    • 13.3.2. Minimally Invasive Surgeries
      • 13.3.2.1. Transurethral Resection of the Prostate (TURP)
      • 13.3.2.2. Transurethral Incision of the Prostate (TUIP)
      • 13.3.2.3. Robotic Surgeries
      • 13.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
      • 13.3.2.5. Prostatic Urethral Lift
      • 13.3.2.6. Others
    • 13.3.3. Laser Therapy
    • 13.3.4. Others
  • 13.4. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
    • 13.4.1. Hospitals
    • 13.4.2. Ambulatory Surgical Centers
    • 13.4.3. Specialty Clinics
    • 13.4.4. Others
  • 13.5. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
    • 13.6.1. By Treatment
    • 13.6.2. By End-user
    • 13.6.3. By Country/Sub-region

14. Competitive Landscape (Pharmaceutical Companies)

  • 14.1. Company Profiles
    • 14.1.1. Abbott
      • 14.1.1.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.1.2. Financials
      • 14.1.1.3. Recent Developments
      • 14.1.1.4. Strategy
    • 14.1.2. Allergan plc
      • 14.1.2.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.2.2. Financials
      • 14.1.2.3. Recent Developments
      • 14.1.2.4. Strategy
    • 14.1.3. Astellas Pharma, Inc.
      • 14.1.3.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.3.2. Financials
      • 14.1.3.3. Recent Developments
      • 14.1.3.4. Strategy
    • 14.1.4. Asahi Kasei Corporation
      • 14.1.4.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.4.2. Financials
      • 14.1.4.3. Recent Developments
      • 14.1.4.4. Strategy
    • 14.1.5. Boehringer Ingelheim GmbH
      • 14.1.5.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.5.2. Financials
      • 14.1.5.3. Recent Developments
      • 14.1.5.4. Strategy
    • 14.1.6. GlaxoSmithKline plc
      • 14.1.6.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.6.2. Financials
      • 14.1.6.3. Recent Developments
      • 14.1.6.4. Strategy
    • 14.1.7. Pfizer, Inc.
      • 14.1.7.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.7.2. Financials
      • 14.1.7.3. Recent Developments
      • 14.1.7.4. Strategy
    • 14.1.8. Sanofi
      • 14.1.8.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.8.2. Financials
      • 14.1.8.3. Recent Developments
      • 14.1.8.4. Strategy
    • 14.1.9. Teva Pharmaceutical Industries Ltd.
      • 14.1.9.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.9.2. Financials
      • 14.1.9.3. Recent Developments
      • 14.1.9.4. Strategy
    • 14.1.10. Merck & Co., Inc.
      • 14.1.10.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.10.2. Financials
      • 14.1.10.3. Recent Developments
      • 14.1.10.4. Strategy

15. Competitive Landscape (Medical Devices/Service Provider Organizations)

  • 15.1. Company Profiles
    • 15.1.1. Boston Scientific Corporation
      • 15.1.1.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.1.2. Financials
      • 15.1.1.3. Recent Developments
      • 15.1.1.4. Strategy
    • 15.1.2. Teleflex Incorporated
      • 15.1.2.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.2.2. Financials
      • 15.1.2.3. Recent Developments
      • 15.1.2.4. Strategy
    • 15.1.3. Endo International plc
      • 15.1.3.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.3.2. Financials
      • 15.1.3.3. Recent Developments
      • 15.1.3.4. Strategy
    • 15.1.4. Urologix, LLC
      • 15.1.4.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.4.2. Financials
      • 15.1.4.3. Recent Developments
      • 15.1.4.4. Strategy
    • 15.1.5. LISA Laser
      • 15.1.5.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.5.2. Financials
      • 15.1.5.3. Recent Developments
      • 15.1.5.4. Strategy
    • 15.1.6. Olympus Corporation
      • 15.1.6.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.6.2. Financials
      • 15.1.6.3. Recent Developments
      • 15.1.6.4. Strategy

List of Tables

  • TABLE 1 Prostate Cancer Therapeutics : Pipeline Analysis - Phase III (1/2)
  • TABLE 2 Prostate Cancer Therapeutics : Pipeline Analysis - Phase III (2/2)
  • TABLE 3 Prostate Cancer Therapeutics : Pipeline Analysis - Phase II (1/2)
  • TABLE 4 Prostate Cancer Therapeutics : Pipeline Analysis - Phase II (2/2)
  • TABLE 5 Prostate Cancer Therapeutics : Pipeline Analysis - Phase I
  • TABLE 6 2015 Patient Population Break Down
  • TABLE 7 Number of Surgeries (Unit Procedures) Performed in United States (2018)
  • TABLE 8 Summary of Current BPH Treatments in U.S.
  • TABLE 9 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 10 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 11 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017-2027
  • TABLE 12 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by End-user, 2017-2027
  • TABLE 13 Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2016-2026
  • TABLE 14 North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country, 2016-2026
  • TABLE 15 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 16 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 17 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017-2027
  • TABLE 18 North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2016-2026
  • TABLE 19 Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • TABLE 20 Europe Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 21 Europe Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 22 Europe Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017-2027
  • TABLE 23 Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2027
  • TABLE 24 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • TABLE 25 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 26 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 27 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017-2027
  • TABLE 28 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2027
  • TABLE 29 Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • TABLE 30 Latin America Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 31 Latin America Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 32 Latin America Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017-2027
  • TABLE 33 Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2027
  • TABLE 34 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • TABLE 35 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 36 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 37 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017-2027
  • TABLE 38 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2027

List of Figures

  • FIG. 1 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, 2017-2027
  • FIG. 2 Global Benign Prostatic Hyperplasia Treatment Market Value Share, by Treatment, 2018
  • FIG. 3 Global Benign Prostatic Hyperplasia Treatment Market Value Share, by Drug Class, 2018
  • FIG. 4 Global Benign Prostatic Hyperplasia Treatment Market Value Share, by End-user, 2018
  • FIG. 5 Global Benign Prostatic Hyperplasia Treatment Market Value Share, by Minimally Invasive Surgery, 2018
  • FIG. 6 Global Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • FIG. 7 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Drug Class, 2017-2027
  • FIG. 8 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Minimally Invasive Surgeries, 2017-2027
  • FIG. 9 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Laser Therapy, 2017-2027
  • FIG. 10 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Others, 2017-2027
  • FIG. 11 Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2019-2027
  • FIG. 12 Global Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • FIG. 13 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Hospitals, 2017-2027
  • FIG. 14 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Ambulatory Surgical Centers, 2017-2027
  • FIG. 15 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Specialty Clinics, 2017-2027
  • FIG. 16 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Others, 2017-2027
  • FIG. 17 Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2019-2027
  • FIG. 18 Global Benign Prostatic Hyperplasia Treatment Market Value Share (%), by Region, 2018 and 2026
  • FIG. 19 Global Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Region, 2018-2026
  • FIG. 20 North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • FIG. 21 North America Benign Prostatic Hyperplasia Treatment Market Value Share, by Country, 2017 and 2026
  • FIG. 22 North America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country, 2018-2026
  • FIG. 23 North America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2017 and 2026
  • FIG. 24 North America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2018-2026
  • FIG. 25 North America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2017 and 2026
  • FIG. 26 North America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2018-2026
  • FIG. 27 Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019-2027
  • FIG. 28 Europe Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
  • FIG. 29 Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • FIG. 30 Europe Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • FIG. 31 Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019-2027
  • FIG. 32 Europe Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • FIG. 33 Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019-2027
  • FIG. 34 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019-2027
  • FIG. 35 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
  • FIG. 36 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • FIG. 37 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • FIG. 38 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019-2027
  • FIG. 39 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • FIG. 40 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019-2027
  • FIG. 41 Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019-2027
  • FIG. 42 Latin America Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
  • FIG. 43 Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • FIG. 44 Latin America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • FIG. 45 Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019-2027
  • FIG. 46 Latin America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • FIG. 47 Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019-2027
  • FIG. 48 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019-2027
  • FIG. 49 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
  • FIG. 50 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • FIG. 51 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • FIG. 52 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019-2027
  • FIG. 53 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • FIG. 54 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019-2027
  • FIG. 55 Global Benign Prostatic Hyperplasia Treatment Devices Market Share Analysis, by Company, 2018
  • FIG. 56 GlaxoSmithKline plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2018
  • FIG. 57 GlaxoSmithKline plc. R&D Expenses and Selling, General and Administration Expenses (US$ Bn) - Company Level, 2015-2018
  • FIG. 58 GlaxoSmithKline plc. Breakdown of Net Sales, by Region/Country (Company Level), 2018
  • FIG. 59 GlaxoSmithKline plc. Breakdown of Net Sales, by Business Segment (Overall Company Level), 2018
  • FIG. 60 Sanofi R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • FIG. 61 Sanofi Breakdown of Net Sales (%), by Region/Country, 2018
  • FIG. 62 Sanofi Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2018
  • FIG. 63 Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015-2018
  • FIG. 64 Pfizer, Inc. Breakdown of Net Sales, by Region/Country, 2018
  • FIG. 65 Pfizer, Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2015-2018
  • FIG. 66 Pfizer, Inc. Breakdown of Net Sales, by Business Segment (%), 2018
  • FIG. 67 Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • FIG. 68 Teva Pharmaceutical Industries Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • FIG. 69 Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region, 2018
  • FIG. 70 Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Operating Segment, 2017
  • FIG. 71 Abbott Laboratories Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2018
  • FIG. 72 Abbott Laboratories R&D Intensity and Sales & Marketing Intensity - Company Level, 2016-2018
  • FIG. 73 Abbott Laboratories Breakdown of Net Sales, by Segment, 2018
  • FIG. 74 Abbott Breakdown of Net Sales (%), by Country/Sub-region, 2018
  • FIG. 75 Allergan plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • FIG. 76 Allergan plc Breakdown of Net Sales (%), by Geography, 2018
  • FIG. 77 Allergan plc R&D Expenses and Marketing & Sales Intensity (%) 2016-2018
  • FIG. 78 Allergan plc Breakdown of Net Sales (%), by Business Segment, 2018
  • FIG. 79 Endo Pharmaceuticals, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
  • FIG. 80 Endo Pharmaceuticals, Inc. Breakdown of Net Sales (%), by Region, 2016
  • FIG. 81 Endo Pharmaceuticals, Inc. total Acquisition-related and Integration Items, Expenses in 2016-2018
  • FIG. 82 Endo Pharmaceuticals, Inc. Breakdown of Net Sales (%), by Specialty Products, 2018
  • FIG. 83 Boehringer Ingelheim GmbH Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2018
  • FIG. 84 Boehringer Ingelheim GmbH Breakdown of Net Sales, by Region (Company Level), 2018
  • FIG. 85 Boehringer Ingelheim GmbH Breakdown of Net Sales, by Business and Business Segment Level, 2017
  • FIG. 86 Boehringer Ingelheim GmbH R&D Expenditure (US$ Mn), 2016-2018
  • FIG. 87 Merck & Co., Inc. Break-up of Net Sales, by Region, 2017
  • FIG. 88 Merck & Co., Inc. Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • FIG. 89 Merck & Co., Inc. R&D Intensity (%) - Company Level or Segment Level, 2014-2017
  • FIG. 90 Asahi Kasei Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • FIG. 91 Asahi Kasei Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • FIG. 92 Asahi Kasei Corporation Breakdown of Net Sales (%), by Business Segment, 2018
  • FIG. 93 Astellas Pharma, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2018
  • FIG. 94 Astellas Pharma, Inc. Breakdown of Net Sales (%), by Region, 2016
  • FIG. 95 Astellas Pharma, Inc. R&D expenses (US$ Bn) in 2016-2018
  • FIG. 96 Astellas Pharma, Inc. Breakdown of Net Sales (%), by Main Products, 2018
  • FIG. 97 Teleflex Incorporated, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • FIG. 98 Teleflex Incorporated, Breakdown of Net Sales (%), by Business Segment, 2018
  • FIG. 99 Teleflex Incorporated, Breakdown of Net Sales (%), by Geography, 2018
  • FIG. 100 Boston Scientific Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
  • FIG. 101 Boston Scientific Corporation Breakdown of Net Sales (%), by Business Segment, 2018
  • FIG. 102 Boston Scientific Corporation Breakdown of Net Sales (%), by Country, 2017
  • FIG. 103 Boston Scientific Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • FIG. 104 Olympus Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2018
  • FIG. 105 Olympus Corporation Breakdown of Net Sales (%), by Region, 2018
  • FIG. 106 Olympus Corporation Breakdown of Net Sales (%), by Medical Business Segment, 2018